Thermo Fisher Scientific has expanded its strategic partnership with Agios Pharmaceuticals to co-develop second companion diagnostic (CDx) for oncology.

As part of the agreement, the companies will jointly validate the biomarkers for a test that will use Thermo Fisher’s Oncomine Precision Assay, which runs on the new Ion Torrent Genexus System.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The test will be used globally to detect low-grade glioma (LGG) patients with isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations who may be eligible for Agios’ investigational inhibitor vorasidenib (AG-881).

Vorasidenib is currently under evaluation in the Phase III INDIGO study.

Thermo Fisher Scientific clinical next-generation sequencing and oncology president Garret Hampton said: “The speed of the Genexus System in combination with the Oncomine Precision Assay has the potential to change the pace in which those diagnosed with LGG can be stratified and directed to a potentially more effective treatment in the future.

“We are committed to collaborating with leading pharmaceutical partners to make precision medicine accessible to more patients everywhere.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the agreement, Thermo Fisher will maintain the rights to commercialise the new test globally and seek clearance from the regulatory agencies.

The companies initiated a partnership in 2017 to develop and commercialise a CDx to identify patients with IDH1 mutant cholangiocarcinoma who may be eligible for Agios’ TIBSOVO (ivosidenib or AG-120) as part of ClarIDHy Phase III clinical study.

In March, Thermo Fisher partnered with Janssen Biotech to develop a CDx to identify variant-positive patients for enrolment into clinical trials focused on non-small cell lung cancer (NSCLC).